Total laparoscopic hysterectomy for oncological indications with outcomes stratified by age

Katherine A. O'Hanlan, Gloria Shining Huang, Lisbeth Lopez, Anne Caroline Garnier

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

We hypothesize that there is no difference in surgical outcomes of patients undergoing total laparoscopic hysterectomy (TLH) for various oncological indications when stratified by age categories. Data were analyzed by ANOVA and chi-square test with significance of P < 0.05, stratified by age (young: <50 years, middle: 50-64, senior age 65+). There were 208 patients, age 26-86 years: 85 young, 82 middle, and 41 senior women. Preoperative diagnoses included 13 cases of cervical dysplasia, 10 cervical or upper vaginal carcinoma, 60 endometrial neoplasias, 22 prophylaxes of familial ovarian carcinoma, 95 with complex pelvic mass, and 8 with early ovarian carcinoma. Mean body mass index (BMI) was 27.2 kg/m 2 for all groups. Parity increased with age (1.0, 1.3, and 2.0; P = 0.001). Surgical duration was longer for young than middle or senior (168, 147, and 140 min, P = 0.0095). All groups had a similar mean blood loss (133 cc, ns) and similar mean length of hospital stay (1.8 days, ns). Overall complication rate was 7.7% with no variance by age: one seroma, one hematoma, one diverticulitis, one incisional hernia, one vaginal nonhealing, one adhesive bowel obstruction, and five urologic complications (two bladder, three ureteral; four treated with catheter or stent, one reimplant. Reoperation was required in 2.8%. Null hypothesis accepted: TLH appears feasible and safe for oncological practice indications throughout the life span. This pilot data can facilitate guidelines for a randomized controlled trial of TLH with TAH and laparoscopic assisted vaginal hysterectomy (LAVH).

Original languageEnglish (US)
Pages (from-to)196-203
Number of pages8
JournalGynecologic Oncology
Volume95
Issue number1
DOIs
StatePublished - Oct 2004

Fingerprint

Hysterectomy
Length of Stay
Uterine Cervical Dysplasia
Carcinoma
Seroma
Vaginal Hysterectomy
Diverticulitis
Chi-Square Distribution
Endometrial Neoplasms
Parity
Reoperation
Hematoma
Adhesives
Stents
Analysis of Variance
Urinary Bladder
Body Mass Index
Catheters
Randomized Controlled Trials
Guidelines

Keywords

  • Age
  • Laparoscopic assisted vaginal hysterectomy
  • Total laparoscopic hysterectomy

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Total laparoscopic hysterectomy for oncological indications with outcomes stratified by age. / O'Hanlan, Katherine A.; Huang, Gloria Shining; Lopez, Lisbeth; Garnier, Anne Caroline.

In: Gynecologic Oncology, Vol. 95, No. 1, 10.2004, p. 196-203.

Research output: Contribution to journalArticle

O'Hanlan, Katherine A. ; Huang, Gloria Shining ; Lopez, Lisbeth ; Garnier, Anne Caroline. / Total laparoscopic hysterectomy for oncological indications with outcomes stratified by age. In: Gynecologic Oncology. 2004 ; Vol. 95, No. 1. pp. 196-203.
@article{b791712788d542e685df11023c72816c,
title = "Total laparoscopic hysterectomy for oncological indications with outcomes stratified by age",
abstract = "We hypothesize that there is no difference in surgical outcomes of patients undergoing total laparoscopic hysterectomy (TLH) for various oncological indications when stratified by age categories. Data were analyzed by ANOVA and chi-square test with significance of P < 0.05, stratified by age (young: <50 years, middle: 50-64, senior age 65+). There were 208 patients, age 26-86 years: 85 young, 82 middle, and 41 senior women. Preoperative diagnoses included 13 cases of cervical dysplasia, 10 cervical or upper vaginal carcinoma, 60 endometrial neoplasias, 22 prophylaxes of familial ovarian carcinoma, 95 with complex pelvic mass, and 8 with early ovarian carcinoma. Mean body mass index (BMI) was 27.2 kg/m 2 for all groups. Parity increased with age (1.0, 1.3, and 2.0; P = 0.001). Surgical duration was longer for young than middle or senior (168, 147, and 140 min, P = 0.0095). All groups had a similar mean blood loss (133 cc, ns) and similar mean length of hospital stay (1.8 days, ns). Overall complication rate was 7.7{\%} with no variance by age: one seroma, one hematoma, one diverticulitis, one incisional hernia, one vaginal nonhealing, one adhesive bowel obstruction, and five urologic complications (two bladder, three ureteral; four treated with catheter or stent, one reimplant. Reoperation was required in 2.8{\%}. Null hypothesis accepted: TLH appears feasible and safe for oncological practice indications throughout the life span. This pilot data can facilitate guidelines for a randomized controlled trial of TLH with TAH and laparoscopic assisted vaginal hysterectomy (LAVH).",
keywords = "Age, Laparoscopic assisted vaginal hysterectomy, Total laparoscopic hysterectomy",
author = "O'Hanlan, {Katherine A.} and Huang, {Gloria Shining} and Lisbeth Lopez and Garnier, {Anne Caroline}",
year = "2004",
month = "10",
doi = "10.1016/j.ygyno.2004.07.023",
language = "English (US)",
volume = "95",
pages = "196--203",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Total laparoscopic hysterectomy for oncological indications with outcomes stratified by age

AU - O'Hanlan, Katherine A.

AU - Huang, Gloria Shining

AU - Lopez, Lisbeth

AU - Garnier, Anne Caroline

PY - 2004/10

Y1 - 2004/10

N2 - We hypothesize that there is no difference in surgical outcomes of patients undergoing total laparoscopic hysterectomy (TLH) for various oncological indications when stratified by age categories. Data were analyzed by ANOVA and chi-square test with significance of P < 0.05, stratified by age (young: <50 years, middle: 50-64, senior age 65+). There were 208 patients, age 26-86 years: 85 young, 82 middle, and 41 senior women. Preoperative diagnoses included 13 cases of cervical dysplasia, 10 cervical or upper vaginal carcinoma, 60 endometrial neoplasias, 22 prophylaxes of familial ovarian carcinoma, 95 with complex pelvic mass, and 8 with early ovarian carcinoma. Mean body mass index (BMI) was 27.2 kg/m 2 for all groups. Parity increased with age (1.0, 1.3, and 2.0; P = 0.001). Surgical duration was longer for young than middle or senior (168, 147, and 140 min, P = 0.0095). All groups had a similar mean blood loss (133 cc, ns) and similar mean length of hospital stay (1.8 days, ns). Overall complication rate was 7.7% with no variance by age: one seroma, one hematoma, one diverticulitis, one incisional hernia, one vaginal nonhealing, one adhesive bowel obstruction, and five urologic complications (two bladder, three ureteral; four treated with catheter or stent, one reimplant. Reoperation was required in 2.8%. Null hypothesis accepted: TLH appears feasible and safe for oncological practice indications throughout the life span. This pilot data can facilitate guidelines for a randomized controlled trial of TLH with TAH and laparoscopic assisted vaginal hysterectomy (LAVH).

AB - We hypothesize that there is no difference in surgical outcomes of patients undergoing total laparoscopic hysterectomy (TLH) for various oncological indications when stratified by age categories. Data were analyzed by ANOVA and chi-square test with significance of P < 0.05, stratified by age (young: <50 years, middle: 50-64, senior age 65+). There were 208 patients, age 26-86 years: 85 young, 82 middle, and 41 senior women. Preoperative diagnoses included 13 cases of cervical dysplasia, 10 cervical or upper vaginal carcinoma, 60 endometrial neoplasias, 22 prophylaxes of familial ovarian carcinoma, 95 with complex pelvic mass, and 8 with early ovarian carcinoma. Mean body mass index (BMI) was 27.2 kg/m 2 for all groups. Parity increased with age (1.0, 1.3, and 2.0; P = 0.001). Surgical duration was longer for young than middle or senior (168, 147, and 140 min, P = 0.0095). All groups had a similar mean blood loss (133 cc, ns) and similar mean length of hospital stay (1.8 days, ns). Overall complication rate was 7.7% with no variance by age: one seroma, one hematoma, one diverticulitis, one incisional hernia, one vaginal nonhealing, one adhesive bowel obstruction, and five urologic complications (two bladder, three ureteral; four treated with catheter or stent, one reimplant. Reoperation was required in 2.8%. Null hypothesis accepted: TLH appears feasible and safe for oncological practice indications throughout the life span. This pilot data can facilitate guidelines for a randomized controlled trial of TLH with TAH and laparoscopic assisted vaginal hysterectomy (LAVH).

KW - Age

KW - Laparoscopic assisted vaginal hysterectomy

KW - Total laparoscopic hysterectomy

UR - http://www.scopus.com/inward/record.url?scp=4644273971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644273971&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2004.07.023

DO - 10.1016/j.ygyno.2004.07.023

M3 - Article

C2 - 15385132

AN - SCOPUS:4644273971

VL - 95

SP - 196

EP - 203

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -